Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Septal Defect, Heart Clear all
Terminated No phase listed Observational

Infant Weight Gain With Trisomy 21 and CAVC

NCT00327951
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 1 Year
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated No phase listed Observational

Nickel Allergy With Septal Closure Devices

NCT01068366
View directory record Official record
Conditions
Atrial Septal Defect, Patent Foramen Ovale, Allergic Reaction to Nickel
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

NCT02744677
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Not yet recruiting Not applicable Interventional

Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?

NCT07393243
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
Clear priming of the bypass pump
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

NCT04452188
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
Interventions
Normoxia (with controlled re-oxygenation), Standard of care ventilation
Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 29 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

NobleStitch EL STITCH Trial is a PFO Comparative Trial

NCT04339699
View directory record Official record
Conditions
Foramen Ovale, Patent, Stroke, Ischemic
Interventions
NobleStitch™EL Suture Mediated Closure System, Amplatzer PFO Occluder
Device
Lead sponsor
Nobles Medical Technologies II Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

NCT07172464
View directory record Official record
Conditions
PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale, PFO-associated Stroke
Interventions
Recross P3 Occluder (P3O) System
Device
Lead sponsor
Recross Cardio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Los Angeles, California • Gainsville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

NCT01711983
View directory record Official record
Conditions
Septal Defect, Atrial
Interventions
GORE® CARDIOFORM Septal Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional

Comparison of Lower vs Upper Extremity Injection Agitated Saline to Identify Patent Foramen Ovale With Echocardiography

NCT07009678
View directory record Official record
Conditions
Patent Foramen Ovale, Cryptogenic Stroke, Embolic Infarction
Interventions
intravenous access in greater saphenous vein compared to upper extremity site.
Diagnostic Test
Lead sponsor
St. John's Hospital
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

NCT02985684
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
GORE® CARDIOFORM ASD Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting No phase listed Observational

Abbott Structural Heart Device Registry

NCT06590467
View directory record Official record
Conditions
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions
Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

NCT02378623
View directory record Official record
Conditions
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 22, 2026, 11:22 AM EDT
Completed No phase listed Observational

Pulmonary Hypertension in Trisomy 21 Patients

NCT00478296
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 8 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Long-term Safety Study of the GORE® HELEX® Septal Occluder

NCT00581308
View directory record Official record
Conditions
Septal Defect, Atrial
Interventions
GORE® HELEX® Septal Occluder
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
Not listed
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

Study of Triostat in Infants During Heart Surgery

NCT00027417
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Liothyronine sodium/triiodothyronine, Cardiopulmonary bypass and cardiac surgery
Drug · Procedure
Lead sponsor
Michael Portman
Other
Eligibility
Up to 2 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

Encore PFO Closure Device - The PerFOrm Trial

NCT05537753
View directory record Official record
Conditions
Patent Foramen Ovale, Cryptogenic Stroke
Interventions
Encore PFO closure device, FDA-approved PFO closure device
Device
Lead sponsor
Encore Medical Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Little Rock, Arkansas • La Jolla, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 11:22 AM EDT
Withdrawn Not applicable Interventional

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

NCT03232450
View directory record Official record
Conditions
Foramen Ovale, Patent
Interventions
Aspirin, Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
View directory record Official record
Conditions
Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Interventions
Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study

NCT00650936
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
AMPLATZER Septal Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated Phase 3 Interventional

ESCAPE Migraine Trial

NCT00267371
View directory record Official record
Conditions
Migraine Disorders, Heart Septal Defects, Atrial
Interventions
PFO Closure with Premere investigational device., Medical management/current medications per standard of care by personal physician.
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
37
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated No phase listed Observational

A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children

NCT02276599
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
Volume expansion
Procedure
Lead sponsor
Brian Schloss
Other
Eligibility
1 Year to 12 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics

NCT01915277
View directory record Official record
Conditions
Transposition of the Great Arteries, Tetralogy of Fallot, Ventricular Septal Defect
Interventions
Dexmedetomidine
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 180 Days
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt

NCT04604015
View directory record Official record
Conditions
Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Right-To-Left Atrial Shunt, Patent Foramen Ovale
Interventions
NeuralBot Investigational System, Transthoracic Echocardiography (TTE)
Diagnostic Test
Lead sponsor
NeuraSignal Inc dba NovaSignal
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Portland, Oregon • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 11:22 AM EDT
Withdrawn Phase 1 Interventional

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

NCT01825369
View directory record Official record
Conditions
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions
IV L-carnitine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 22, 2026, 11:22 AM EDT